Topic
Drug Compounding
46 published works
Focus on Regulation
New Guidance Makes Clear that FDA Is Focused on Insanitary Conditions at Pharmacy Compounders
By Robert Church, Jim Johnson, Christopher Fanelli
Today, FDA published yet another draft guidance targeting drug compounders, entitled Insanitary Conditions at Compounding Facilities (the Draft Guidance). Notably, it makes clear to pharmacy compounders that although they may…
Health Law Update
FDA Committee to Continue Considering Drug Compounding Issues
By Lee H. Rosebush, Dena Kessler
The advisory committee tasked with providing advice on medical, scientific and technical issues to the Food and Drug Administration (FDA) on compounded drugs is slated to continue its examination of…
Health Law Update
FDA Establishes Docket for Public Comments on Drug Compounding
The Food and Drug Administration (FDA) recently announced a new docket for public comments on the compounding of human drug products under sections 503A and 503B of the Federal Food,…
Health Law Update
FDA Issues Draft Memorandum of Understanding for 503A Drug Compounding
By Lee H. Rosebush, Cory J. Fox, Dena Kessler
Included in the flurry of guidance documents recently issued by the FDA concerning human drug compounding is a long-awaited document of great importance to mail-order pharmacy compounders and entities that…
Health Law Update
FDA Guidance Documents Change Compounding Landscape
By Lee H. Rosebush, Cory J. Fox, Nita Garg, Dena Kessler
Almost a year and a half after adoption of the Drug Quality and Security Act (DQSA) in November 2013, which revised federal oversight of drug compounding, the Food and Drug…
Sentencing Law and Policy
Cloudy with (less of) a chance of executions in Georgia
Main March 4, 2015Cloudy with (less of) a chance of executions in GeorgiaAs reported in this Time piece, headlined "Georgia Postpones 2 Executions Over ‘Cloudy’ Drugs," the forecast in the…
Focus on Regulation
FDA Publishes Draft Guidances and Memorandum of Understanding on Drug Compounding and Repackaging
By Mike Druckman, David Fox, Philip Katz, Delia A. Deschaine, Sari Bourne
On February 13, 2015, FDA issued four draft guidance documents and a draft memorandum of understanding (MOU) regarding the compounding of drug and biological products and the regulation of outsourcing…
Health Law Update
Now’s the Time to Comment on the FDA’s New Draft Documents on Compounding Policy
By Lee H. Rosebush, Cory J. Fox
The U.S. Food and Drug Administration (FDA) has released five new draft documents related to drug compounding and repackaging by “outsourcing facilities,” state-licensed pharmacies, federal facilities and other healthcare entities.…
Health Industry Washington Watch
OIG Reviews Oversight of Compounded Pharmaceuticals Used in Hospitals
The OIG has issued another report examining the safety of compounded sterile preparations (CSPs) used in hospitals, in response to a 2012 meningitis outbreak caused by contaminated injections. This report,…
Focus on Regulation
FDA Issues Interim cGMP Guidance for Outsourcing Facilities
By Mike Druckman, Jim Johnson, Michael Moskowitz
On July 1, the Food and Drug Administration (FDA) issued interim guidance describing the Agency’s expectations for compliance with current Good Manufacturing Practice (cGMP) requirements for compounding outsourcing facilities under…